SCHEMBL4483460

SCHEMBL4483460

CN(C)C(=O)c1c2c(c(O)c(=O)n1-c1ccc([N+](=O)[O-])cc1)C(=O)N(Cc1ccc(F)c(Cl)c1)CC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
PMM2 O15305 1/20 0.34
MPI P34949 1/20 0.34
PHOSPHO1 Q8TCT1 1/20 0.34
LMNA P02545 1/20 0.34
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
KMT2A Q03164 1/20 0.33
NPBWR1 P48145 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4480516 0.90 LMNA (0.35) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4484250 0.90 PDK1 (0.34) HDAC1HDAC6AKR1B1
SCHEMBL4480319 0.89 AKR1B1 (0.35) HDAC1LMNAAKR1B1
SCHEMBL4490025 0.89 MAPK8 (0.34) MAPTKMT2AMCHR1AKR1B1
SCHEMBL4489427 0.88 AKR1B1 (0.33) HDAC1HDAC6MAPTAKR1B1
SCHEMBL4500232 0.88 CA2 (0.34) KMT2AHTTAKR1B1
SCHEMBL4486052 0.88 METAP2 (0.35) HDAC1HDAC6OPRK1AKR1B1
SCHEMBL4484270 0.88 AKR1B1 (0.32) MAPTAKR1B1
SCHEMBL4487534 0.88 AKR1B1 (0.32) AKR1B1
SCHEMBL4486606 0.87 METAP2 (0.36) CCR3AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US claimed
EP-1725556-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005087768-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO claimed
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179196-A1 Hiv integrase inhibitors REV1, TYMP, POLR2H HDAC3 1553/4885HDAC4 847/4885HDAC1 857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.